Get the Stockscreener App
511.33
0.03%
-0.41
Vertex Pharmaceuticals Inc stock is traded at $511.33, with a volume of 198.74K.
It is down -0.03% in the last 24 hours and up +6.51% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$511.74
Open:
$511.78
24h Volume:
198.74K
Relative Volume:
0.13
Market Cap:
$131.41B
Revenue:
$11.02B
Net Income/Loss:
$-535.60M
P/E Ratio:
-232.42
EPS:
-2.2
Net Cash Flow:
$-978.00M
1W Performance:
-0.12%
1M Performance:
+6.51%
6M Performance:
+10.79%
1Y Performance:
+22.97%
1-Day Range:
$507.08
$512.71
1-Week Range:
$501.00
$515.67
52-Week Range:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
511.38 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
655.38 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
287.98 | 37.54B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ARGX
Argen X Se Adr
|
609.18 | 37.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
253.46 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals’ SWOT analysis: stock poised for growth amid challenges - Investing.com
JPMorgan Adjusts Price Target on Vertex Pharmaceuticals to $512 From $500, Keeps Overweight Rating - Marketscreener.com
Jim Cramer on Vertex (VRTX): “A Revolutionary Anti-Pain Drug” - Insider Monkey
Jim Cramer on Vertex (VRTX): "A Revolutionary Anti-Pain Drug" - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Nasdaq
Insider Sell: David Altshuler Sells Shares of Vertex Pharmaceuti - GuruFocus.com
Insider Sell: David Altshuler Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus.com
Should You Buy Vertex Pharmaceuticals Stock At $510? - Trefis
Vertex Pharmaceuticals (VRTX) Rises But Trails Market: What Investors Should Know - Yahoo Finance
Cystic Fibrosis Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Is Vertex Pharmaceuticals (VRTX) the Best Diabetes Stock to Buy According to Billionaires? - Insider Monkey
Global mRNA-based Vaccines and Therapeutics Market is expected to Grow at a decent CAGR during the Study Period (2019-2032) | DelveInsight - The Globe and Mail
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack - Yahoo Finance
Ed Kaye, founding CEO of Stoke Therapeutics, steps down - The Business Journals
Vertex Pharmaceuticals (VRTX): One of the Best Biotech Stocks to Buy According to Billionaires - Insider Monkey
Vertex's Pain Drug: Big Pharma's Next Major Success? - MSN
Is Vertex Pharmaceuticals (VRTX) Among the Best High Growth Stocks? - Insider Monkey
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
DA Davidson maintains Buy on Vertex shares, target $34 By Investing.com - Investing.com UK
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation - The Motley Fool
13 High Growth Large Cap Stocks To Invest In - Insider Monkey
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain - Business Wire
Layoff Tracker: GRO Biosciences Cuts Staff Amid Quest for Strategic Alternatives - BioSpace
Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today - Yahoo Finance
$100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Benzinga
A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics - Benzinga
Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Rating Upgraded by StockNews.com - Defense World
Vertex Pharmaceuticals EVP sells $1.6 million in stock By Investing.com - Investing.com Australia
Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals EVP sells $1.62 million in stock - Investing.com India
Vertex Pharmaceuticals EVP sells $1.6 million in stock - Investing.com
Vertex Pharmaceuticals Executives Sell Shares - TradingView
Vertex Pharmaceuticals CFO sells shares worth $1.65 million - Investing.com
Why Vertex Pharmaceuticals Incorporated (VRTX) is the Best Pharma Stock to Buy According to Hedge Funds - Insider Monkey
Should You Consider Adding Vertex Pharmaceuticals Incorporated (VRTX) to Your Portfolio? - MSN
Why Is Vertex (VRTX) Up 7.3% Since Last Earnings Report? - Yahoo Finance
Where Will Vertex Pharmaceuticals Be in 10 Years? - sharewise
Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA - PMLiVE
3 Reasons to Avoid VRTX and 1 Stock to Buy Instead - Yahoo Finance
Rep. Jefferson Shreve Purchases Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Defense World
Vertex at Leerink: Strategic Moves and Growth Prospects - Investing.com
UK MHRA approves Vertex’s Alyftrek for cystic fibrosis - Pharmaceutical Business Review
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Jones Financial Companies Lllp - Defense World
UnitedHealth slots Vertex's non-opioid pain med at top of tiered formulary - FirstWord Pharma
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies - Benzinga
Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment - Yahoo Finance
Vertex Pharmaceuticals Says Journavx Non-Opioid Pain Killer Added to Optum Formulary - Marketscreener.com
Vertex Announces UK Mhra Approval Of Alyftrek -March 07, 2025 at 11:32 am EST - Marketscreener.com
Vertex Pharmaceuticals Gets UK Regulatory Approval for Alyftrek to Treat Cystic Fibrosis - Marketscreener.com
(Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
Vertex Pharmaceuticals' Triple Combination Cystic Fibrosis Therapy Alyftrek Receives Approval in UK - Marketscreener.com
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):